Figure 4
Figure 4. Functional assays of anti-C2 MAbs. (A) Representative Bethesda assays for a type I MAb (I89, ●) and a type II MAb (F178, ▵). (B) Inhibition of binding of fVIII to VWF by 3 representative anti-C2 MAbs. The MAbs shown are 3E6 (▿), F100 (○), and I89 (●). (C) Inhibition of binding of fVIII to phospholipid by the 3 anti-C2 MAbs shown in panel B. Error bars represent sample standard deviations of 3 to 12 replicates.

Functional assays of anti-C2 MAbs. (A) Representative Bethesda assays for a type I MAb (I89, ●) and a type II MAb (F178, ▵). (B) Inhibition of binding of fVIII to VWF by 3 representative anti-C2 MAbs. The MAbs shown are 3E6 (▿), F100 (○), and I89 (●). (C) Inhibition of binding of fVIII to phospholipid by the 3 anti-C2 MAbs shown in panel B. Error bars represent sample standard deviations of 3 to 12 replicates.

Close Modal

or Create an Account

Close Modal
Close Modal